Clinique Belhara
- Address
- 2 Allée du Dr Robert Lafon, 64100 Bayonne, France
Respiratory & Circulatory Physiological Research
Clinique Belhara’s pneumology department is exploring novel antifungal strategies for chronic pulmonary aspergillosis and assessing innovative therapies for limited‑disease small cell lung cancer in frail patients. The focus is on improving clinical and radiological outcomes while enhancing quality of life for those with respiratory infections and thoracic malignancies.
- Chronic pulmonary aspergillosis
- Limited disease small cell lung cancer
- Combination antifungal regimens
- Maintenance immunotherapy after chemoradiotherapy
These studies aim to determine whether new treatment combinations can extend survival and reduce disease progression in respiratory patients at the Bayonne site.
Digestive System Cancer Research
The site conducts a range of trials targeting gastro‑intestinal malignancies, from colon carcinoma to metastatic colorectal cancer with high immune infiltration. Research includes personalized neoadjuvant chemotherapy for elderly colon cancer patients and innovative chemotherapy delivery methods for liver‑limited disease.
- Colon carcinoma and rectal cancer with liver metastasis
- Microsatellite stable metastatic colorectal cancer
- Small bowel adenocarcinoma
- Intra‑arterial oxaliplatin versus intravenous administration
- Neoadjuvant chemotherapy in elderly patients
The overarching goal is to refine treatment sequences and improve long‑term disease‑free survival for digestive system cancers.
Prostate Cancer Trials
Investigators at Clinique Belhara are evaluating targeted DNA‑repair inhibition combined with androgen‑receptor blockade for both castration‑resistant and castration‑sensitive prostate cancer. Trials also focus on patients with specific DDR gene mutations to assess whether personalized combinations can delay progression.
- Metastatic castration‑resistant prostate cancer
- Metastatic castration‑sensitive prostate cancer
- DDR‑deficient prostate cancer subgroups
- Combination of talazoparib with enzalutamide
By testing these novel regimens, the research seeks to extend radiographic progression‑free survival and offer new options for men with advanced disease.
Non‑Muscle Invasive Bladder Cancer Research
A dedicated bladder‑cancer program at the Bayonne facility investigates immunotherapy‑enhanced BCG treatment for high‑risk non‑muscle invasive bladder cancer, including both BCG‑naïve and BCG‑unresponsive populations. The trials compare new agents with standard BCG to improve event‑free survival.
- High‑risk non‑muscle invasive bladder cancer
- BCG‑naïve cohort
- BCG‑unresponsive carcinoma in situ
- PF‑06801591 combined with BCG
These studies aim to establish more effective maintenance strategies and reduce recurrence rates for patients who cannot rely on conventional BCG alone.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Belhara
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy of Itraconazole and Nebulised Amphotericin B in Non-Immunocompromised Chronic Pulmonary Aspergillosis Patients | Centre Hospitalier Universitaire De Poitiers | Phase III | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 3 | Unknown | 2024-02-26 | 2026-05-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.